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Appendix I 
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Appendix II 
 
Frozen tissues specimens used in mRNA QPCR analysis 
No Sample Type Age Ethnic Sex Diagnosis Habits Site 
Broder's 
grade 
 TNM 
1 01-0002-04 NM 80 Indian F SCC BQ gum NA NA 
2 01-0006-04 NM 60 Indian F SCC BQ cheek  NA NA 
3 01-0017-05-3 
NM 
24 Malay M Impacted 8 
No 
Habit 
gum NA NA 
4 01-0018-05-3 NM 25 Malay M Impacted 8 UK gum NA NA 
5 01-0020-05 
NM 
23 Malay F Impacted 8 
No 
Habit 
gum NA NA 
6 01-0007-07-3 (1) NM 35 Malay M Impacted 8 Smoke gum NA NA 
7 01-0001-08-3 
NM 
21 Chinese M Impacted 8 
No 
Habit 
gum NA NA 
8 01-0004-08-3 (1) NM 28 Malay M Impacted 8 Smoke gum NA NA 
9 01-0009-08-3 (1) 
NM 
27 Malay M Impacted 8 
No 
Habit 
gum NA NA 
10 01-0011-08-3 (1) NM 29 Malay M Impacted 8 Smoke gum NA NA 
11 01-0018-08-3 (1) NM 30 Malay M Impacted 8 Smoke gum NA NA 
12 01-0025-08-3 (1) 
NM 
23 Chinese M Impacted 8 
No 
Habit 
gum NA NA 
13 04-0012-04 NM 39 Chinese F SCC Smoke tongue NA NA 
14 04-0001-05  NM 75 Malay F SCC BQ cheek NA NA 
15 04-0003-05 NM 52 Malay M SCC Smoke cheek NA NA 
16 06-0033-04 NM 70 Indian F SCC BQ cheek NA NA 
17 06-0002-05 NM 65 Indian F SCC BQ cheek NA NA 
18 AHN NM 55 Malay M SCC Smoke gum NA NA 
19 01-0002-04 Tumour 80 Indian F SCC BQ gum Well T4N1Mx 
20 01-0005-04 Tumour 55 Malay M SCC 
Smoke, 
Alcohol 
palate Well T4N0M0 
21 01-0006-04 Tumour 60 Indian F SCC BQ cheek Well T4N3M0 
22 01-0017-04 Tumour 74 Indian F SCC BQ tongue Moderate T1NxMx 
23 01-0005-05 (1) Tumour 55 Malay M SCC Smoke maxilla Well T2N0M0 
24 01-0022-05 Tumour 59 Indian F SCC BQ cheek  Moderate T4NxMx 
25 01-0038-05 Tumour 52 Chinese M SCC 
No 
Habit 
tongue Poor T3N0Mx 
26 01-0046-05 Tumour 45 Chinese M SCC Alcohol tongue Moderate T4N1M1 
27 01-0001-06 Tumour 71 Indian F SCC BQ gum Well T3N2bM0 
28 01-0005-06 Tumour 58 Indian  F SCC BQ gum Well T4N0Mx 
29 01-0010-06 Tumour 39 Malay F SCC 
No 
Habit 
tongue UK T4N1Mx 
30 01-0029-06 (t2) Tumour 66 Indian F SCC BQ mandible Well T4NoMo 
31 01-0002-07-1 (1) Tumour 56 Indian F SCC BQ gum Well T4N3M0 
32 01-0022-07 (t1) Tumour 49 Malay M SCC Smoke palate  Well T4NxMx 
33 01-0024-07-1 (t2) Tumour 48 Malay M SCC 
No 
Habit 
tongue Poor T2N0Mx 
34 01-0040-07-1 Tumour 73 Indian M SCC 
Smoke, 
Alcohol 
cheek Well UK 
35 01-0017-08-1 (3) Tumour 58 Chinese M SCC Alcohol cheek UK T4N2bMx 
36 02-0004-04 Tumour 60 Chinese M SCC 
Smoke, 
Alcohol 
FOM Poor T4N2cM0 
37 02-0005-05 Tumour 60 Malay M SCC 
No 
Habit 
cheek UK UK 
38 02-0018-05 Tumour 37 Malay M SCC Smoke cheek Well T4N2M0 
39 03-0004-04 Tumour 56 Malay F SCC UK UK UK UK 
40 04-0004-04 Tumour 53 Chinese M SCC 
Smoke, 
Alcohol 
cheek Well T3NxM0 
41 04-0005-04 Tumour 70 Indian F SCC 
BQ, 
Alcohol 
cheek Well T2N2M0 
42 04-0012-04 Tumour 39 Chinese F SCC Smoke tongue Moderate T2N0M0 
43 04-0001-05 (2) Tumour 75 Malay F SCC BQ maxilla Well T4NoMx 
44 04-0003-05 Tumour 52 Malay M SCC Smoke cheek Moderate T4N2bMx 
45 04-0017-05 Tumour 66 Malay F SCC 
No 
Habit 
tongue Moderate T2N1M0 
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Appendix II, continued 
 
 
Frozen tissues specimens used in mRNA QPCR analysis, continued 
 
 
 
 
 
Note: BQ: betel quid, F: female, FOM: floor of mouth, M: male, NA: not applicable, NM: non-malignant, 
SCC: squamous cell carcinoma, UK: unknown 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
46 04-0010-06 Tumour 50 Indian M SCC Smoke tongue Moderate T3N2bM0 
47 04-0002-06 Tumour 46 Chinese M SCC 
No 
Habit 
mandible Moderate T3N0Mx 
48 04-0006-06 Tumour 71 Indian F SCC BQ cheek Well T4N0Mx 
49 04-0021-06-2 Tumour 48 Malay M SCC Smoke tongue Moderate T1N2bMx 
50 06-0007-04 Tumour 47 Indian F SCC BQ cheek Moderate UK 
51 06-0031-04 Tumour 41 Malay M SCC Smoke cheek Moderate T4NoMx 
52 06-0033-04 Tumour 70 Indian F SCC BQ cheek Moderate T4N0Mx 
53 06-0045-04 Tumour 48 Indian F SCC 
Alcohol, 
BQ 
gum Moderate T4N2bM0 
54 06-0002-05 Tumour 65 Indian F SCC BQ cheek Moderate T2NoMo 
55 06-0009-05 Tumour 30 Chinese F SCC 
No 
Habit 
tongue UK T3N0Mx 
56 06-0026-05 Tumour 71 Indian M SCC Alcohol tongue Moderate T1N0M0 
57 06-0027-05 Tumour 36 Indian M SCC Smoke palate Moderate T4N2bM0 
58 06-0039-05 Tumour 28 Indian F SCC 
No 
Habit 
tongue Well T1NoMx 
59 06-0067-05 Tumour 56 Malay M SCC Smoke tongue  Moderate T3N1Mx 
60 06-0009-06 Tumour 61 others F SCC BQ cheek Well T4NoMx 
61 11-0005-05 Tumour 67 Malay M SCC 
No 
Habit 
gum Well T4N0Mx 
62 11-0031-05 Tumour 57 Malay F SCC BQ cheek Moderate T4N0Mx 
63 11-0013-06 Tumour 43 Bidayuh M SCC 
Smoke, 
Alcohol 
tongue Well T3N2aMx 
64 11-0014-06 Tumour 59 Iban F SCC 
No 
Habit 
palate Moderate T4N2bMx 
65 11-0017-06 Tumour 58 Iban F SCC 
Alcohol, 
BQ 
gum Moderate T3N2aMx 
66 11-0005-07-1 Tumour 34 Chinese M SCC Smoke tongue Well T2N1Mx 
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Appendix III 
 
TMaA specimens used for IHC staining 
 
 
 
 
No Case No 
Tissue 
type 
IRPA Age Sex Ethnic Habit Site 
Broder's 
Grading 
TNM 
1 OC(S)2 NM UK UK UK UK UK NA NA NA 
2 D91/92 FEP UK 45 F Indian UK gum NA NA 
3 OC(S)6 NM UK UK UK UK UK UK NA NA 
4 D173/97 FEP UK 50 M Indian UK gum NA NA 
5 OC(S)4 NM UK UK UK UK UK NA NA NA 
6 D30/94 FEP UK 59 F Chinese UK gum NA NA 
7 OC(S)3 NM UK UK UK UK UK UK NA NA 
8 D405/05 FEP UK 61 F Chinese UK gum NA NA 
9 OC(S)1 NM UK UK UK UK UK UK NA NA 
10 D167/04 FEP UK 52 F UK UK gum NA NA 
11 OC(S)8 NM UK UK UK UK UK UK NA NA 
12 D128/06 FEP UK 46 F Chinese UK gum NA NA 
13 OC(S)5 NM UK UK UK UK UK UK NA NA 
14 OC(S)10 NM UK UK UK UK UK UK NA NA 
15 D533/05 FEP UK 81 M Indian UK gum NA NA 
16 D49/87 FEP UK 44 M Chinese UK gum NA NA 
17 D70/81 FEP UK 29 F M UK gum NA NA 
18 D20/81 FEP UK 34 F M UK gum NA NA 
19 3N-1     NM UK UK UK UK UK UK NA NA 
20 3N-2     NM UK UK UK UK UK UK NA NA 
21 3N-3     NM UK UK UK UK UK UK NA NA 
22 3N-D2    NM UK UK UK UK UK UK NA NA 
23 3N-D3    NM UK UK UK UK UK UK NA NA 
24 D556/05 SCC 01-0051-05 62 F Indian BQ, alcohol cheek Well T4N2aMx 
25 D366/06 SCC 06-0045-06 67 F Indian BQ, alcohol cheek Well T1N2bMx 
26 D9/06 SCC 01-0050-05 73 F Indian BQ cheek Moderate T2N0Mx 
27 D406/04 SCC 06-0005-04 60 F Chinese No habit cheek Moderate T2N0Mx 
28 D303/05 SCC 06-0028-05 67 F Indian BQ cheek Well T4N0Mx 
29 D119/06 SCC 06-0009-06 61 F Others BQ cheek Moderate T2N0Mx 
30 D48/06 SCC 06-0001-06 59 F Indian BQ, alcohol cheek Moderate T2N2bMx 
31 D152/06 SCC 06-0015-06 54 F Indian BQ cheek NA T1N0Mx 
32 D212/02 SCC UK 62 F Chinese 
BQ, smoke, 
alcohol 
cheek NA UK 
33 D48/05 SCC 01-0003-05 50 M Indian BQ cheek Well T2N0Mx 
34 D62/06 SCC 06-0002-06 52 F Indian BQ cheek Well T1N0Mx 
35 D84/05 SCC 01-0017-04 74 F Indian BQ cheek Moderate T1NxMx 
36 D273/06 SCC 06-0037-06 49 F Indian BQ cheek Moderate T3N0Mx 
37 D251/05 SCC 06-0018-05 66 F Indian BQ cheek UK T1N0Mx 
38 D517/04 SCC 06-0033-04 70 F Indian BQ cheek Moderate T4N0Mx 
39 D41/05 SCC 06-0045-04 48 F Indian BQ, alcohol cheek Moderate T4N1Mx 
40 D359/03 SCC 06-0028-03 55 M Indian BQ, smoke cheek Moderate T1N0Mx 
41 D137/04 SCC 06-0029-03 63 F Indian BQ cheek Moderate T2N2bMx 
42 D382/03 SCC 01-0022-05 59 F Indian BQ cheek Moderate T1N0Mx 
43 D212/05 SCC 01-0022-05 59 F Indian BQ cheek Moderate T1N0Mx 
44 D68/05 SCC 01-0001-05 65 F Indian BQ cheek Well T4N0Mx 
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Appendix III, continued 
 
 
TMaA specimens used for IHC staining, continued 
 
 
 
Note: BQ: betel quid, F: female, FEP: fibro epithelial polyps, FOM: floor of mouth, M: male, NA: not 
applicable, SCC: squamous cell carcinoma, UK: unknown 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
45 D139/05 SCC 06-0002-05 65 F Indian BQ cheek Moderate T4N0Mx 
46 D373/04 SCC 01-0011-04 50 F Indian BQ cheek Moderate T2N1Mx 
47 D49/07 SCC 06-0005-07 72 F Indian BQ cheek Moderate T4N1Mx 
48 D21/04 SCC 06-0035-03 62 F Indian BQ cheek Moderate T3N1Mx 
49 D79/07 SCC 01-0017-07 61 F Indian BQ cheek Moderate T4N1Mx 
50 D66/06 SCC 11-0006-06 73 M Chinese BQ gum Moderate T4N0Mx 
51 D135/06 SCC 01-0001-06 71 F Indian BQ gum Well T4N2bMx 
52 D182/06 SCC 06-0022-06 72 F Indian No habit gum Well T3N2bMx 
53 D88/05 SCC 01-0005-05 54 M Malay smoke gum Well T4N0Mx 
54 D498/06 SCC 06-0060-06 58 F Indian No habit gum Well T3N2aMx 
55 D579/05 SCC 06-0066-05 69 M Indian No habit gum Well T1N0Mx 
56 D473/05 SCC 06-0040-05 75 F Indian BQ gum Moderate T4N2bMx 
57 D422/04 SCC 06-0031-04 41 M Malay smoke gum Moderate T2N2bMx 
58 D38/07 SCC 06-0066-06 71 F Indian No habit gum Poor T4N0Mx 
59 D146/04 SCC 01-0002-04 80 F Indian BQ gum Well T4N0Mx 
60 D134/07 SCC 01-0022-07 49 M Malay smoke gum Well T4N0Mx 
61 D501/05 SCC 06-0051-05 65 M 
Indian smoke, 
alcohol 
FOM Moderate  T1N2bMx 
62 D486/04 SCC 06-0041-04 68 F Indian BQ, alcohol cheek Poorly T4N0Mx 
63 D241/05 SCC 01-0025-05 38 M Chinese 
smoke, 
alcohol 
tongue Moderate T1N2aMx 
64 D67/07 SCC 06-0003-07 49 M Malay 
smoke, 
alcohol 
tongue Well T1N0Mx 
65 D140/05 SCC 06-0011-05 56 M 
Indian BQ, smoke, 
alcohol 
tongue Poor T1N0Mx 
66 D264/06 SCC 06-0029-06 59 F Indian BQ FOM Moderate T1N2bMx 
67 D34/06 SCC 06-0067-05 57 M Malay smoke tongue Moderate T2N2bMx 
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Appendix IV 
 
Cell line information 
No Cell line Ethnic Gender Age Site 
Broder's 
grade 
Pathology  
staging 
1 ORL48 Sikh Female 79 Gum Well T4N2aMx 
2 ORL115 Malay Female 75 Cheek Well T2NxMx 
3 ORL136 Indian Male 57 Tongue Poor T1N0Mx 
4 ORL150 Indian Male 71 Tongue Moderate T1N0Mx 
5 ORL153 Indian Male 36 Maxillary  Moderate T4N2BMx 
6 ORL156 Chinese Male 38 Tongue Moderate T4N1Mx 
7 ORL166 Malay Female 67 Tongue Moderate T3N1Mx 
8 ORL174 Indian Female 53 Tongue Moderate Unknown 
9 ORL188 Malay Male 57 Tongue Moderate T2N0Mx 
10 ORL195 Indian Female 61 Cheek Well T4N0Mx 
11 ORL196 Indian Female 49 Cheek Moderate T4N1Mx 
12 ORL204 Indian Male 76 Cheek Moderate T4N1Mx 
13 ORL207 Sikh Female 59 Tongue Unknown Unknown 
14 ORL214 Indian Female 49 Cheek Moderate Unknown 
15 ORL215 Indian Male 50 Tongue Moderate T3N2bMx 
16 ORL218N Indian Male 26 Gum Not applicable Not applicable 
17 ORL232N Malay Female 26 Gum Not applicable Not applicable 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 98 
Appendix V 
 
RNA extraction 
 
(A) Frozen tissues  
RNA was extracted from cryosectioned tissues using the RNeasy micro kit (Qiagen, 
Hilden, Germany). Cryosectioned tissues were lysed by vortexing in RLT buffer 
containing 10 μl/ml β-mercaptoethanol (Sigma, MO, USA). Subsequently, 1 volume of 
70% ethanol was mixed to the homogenized lysate and transferred to the spin column 
for centrifugation at 12, 000rpm for 15 sec. Sample was incubated with 80 µl DNase I at 
room temperature for 15 min and washed with 0.5 ml RW1 buffer to remove DNA. 
RNA was washed with 0.5 ml buffer RPE and 0.5 ml 80% ethanol. Finally, the spin 
column was subjected to full speed centrifugation for 5 min to dry the membrane before 
eluting the RNA with 20 µl RNase-free water. 
 
 
(B) Oral cell lines 
Oral cancer cells were grown to 70% confluency. The cell monolayer was rinsed with 
1x PBS and 1 ml of Tri-Reagent (MRC, OH, USA) was added to every 10 cm
2
 of 
culture dish area. Cells were incubated at room temperature for 5 min to allow 
dissociation of nucleoprotein complexes. The homogenate was harvested mixed with 
0.2 ml of chloroform by vigorous shaking for 15 sec. Following incubation at room 
temperature for 15 min, the mixture was centrifuged at 12,000 g for 15 min at 4ºC for 
phase separation. The upper aqueous phase containing the RNA was harvested for RNA 
precipitation by 0.5 ml of isopropanol for 10 mins at room temperature.  Pelleted RNA 
was washed with 75% ethanol and centrifuged at 7,500 g for 5 mins at 4ºC. Finally, 
RNA pellet was air-dried and dissolved in 30 µl of RNase-free water. 
RNA concentration was quantitated by NanoDrop ND-1000 spectrophotometer, 
according to manufacturer’s instruction. RNase-free water was used as blank control. 
The ratio of the absorbance at 260 nm and at 280 nm in the range of 1.8 to 2.3 is used to 
define good RNA quality. Total RNA of 0.5 μg mixed with 5x loading dye was 
subjected to 1% agarose gel electrophoresis containing 0.4 μg/ml ethidium bromide for 
45 min in 1x TAE buffer at 80 V. Bands were visualized under UV light exposure in the 
ChemImager (Alpha Innotech, CA, USA) to check RNA integrity as well as to detect 
any genomic DNA contamination. Band intensity of 28S to18S ribosomal RNA 
subunits in a ratio of 2:1 denotes intact RNA. 
 99 
Appendix VI 
 
 
Positive control for IHC staining  
 
 
 
Figure 1: GNA12 expression in breast cancer tissues. GNA12 was present at high 
level in breast cancer tissues (A) 100x magnification (B) 200x magnification and (C) 
400x magnification. 
 
 
Figure 2: High level of IFITM3 detected in colorectal cancer tissues. (A) 100x 
magnification (B) 200x magnification and (C) 400x magnification. 
 
 
Reagents for IHC 
10x PBS 
NaCl                           80.0g 
NaH2PO4.H2O            14.4g 
KCl                               2.0g 
KH2PO4                                   2.4g 
Adjust to pH 7.4 
Distilled water up to 1L 
Citrate buffer 
Trisodium citrate         2.94g 
Adjust to pH 6.0 
Distilled water up to 1L 
 
 
 
 
 
 
 
A B C 
A B C 
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Appendix VII 
 
Maintenance of cell line 
Oral cancer cell lines were maintained in Dulbecco’s Modified Eagle’s 
Medium/Nutrient mixture F-12 HAM’s (DMEM/F-12) (Hyclone, Utah, USA) complete 
medium, containing 1.2 g/L sodium bicarbonate (Merck, Darmstadt, Germany), 500 
ng/ml hydrocortisone (Sigma, MO, USA) and 10% Fetal Bovine Serum (FBS) (Gibco, 
Auckland, NZ). Normal oral cell lines were cultured in KSFM medium (Gibco, 
Auckland, NZ) supplemented with 25 μg/ml bovine pituitary extract, 0.4 ng/ml 
epidermal growth factor, and 0.09 mM CaCl2.  
Packaging cells 293FT (Invitrogen, CA, USA) and GP-293 (Clontech, CA, USA) 
was cultured in DMEM high glucose medium (Gibco, Auckland, NZ) containing 10% 
FBS, 25 μl of hydrocortisone, and 50 U/ml penicillin (Gibco, Auckland, NZ). In 
addition, 3T3 cells were cultured in DMEM-high glucose complete medium, until 70% 
confluent to harvest the conditioned medium. All cells were grown in tissue culture 
incubator. Medium was changed twice a week. 
Cells were sub-cultured when approaching 70% confluency with Trypsin-EDTA 
solution (Gibco, Auckland, NZ) and neutralized with DMEM/F12 complete medium 
(Freshney, 1994). Cell count was performed by a hemacytometer, whereby 10 µl of cell 
suspension was pipetted into the counting chamber. Cells were enumerated at 10x 
objective under an inverted microscope. The number of cells in all four 1 mm square 
areas was counted and concentration was determined using the formulation below: 
mlcells
squaremmincountcellTotal
ionconcentratcell /10
4
4 4  
Cells were pelleted by centrifugation at 1,000 rpm for 5 min and re-suspended 
with complete medium before being sub-cultured with the required concentration. After 
sub-culturing, cells in excess were aliquoted into cryo vials (Nunc, Roskilde, Denmark) 
at 1 E6/ml in DMEM/F-12 complete medium with 10% DMSO (Sigma, MO, USA), 
and frozen gradually in slow freezing container (Nunc, Roskilde, Denmark) before 
storing in liquid nitrogen. 
 
 
 
 
 
 
 101 
Appendix VIII 
 
Bacteria transformation 
Briefly, plasmids were added to XL1-Blue competent cells and incubated on ice for 30 
min. Cells were subjected to heat shock at 42ºC for 30 sec, and further incubated on ice 
for another 2 min. Following this, 400 µL of LB broth (Pronadisa, Madrid, Spain) was 
added and cells were incubated at 37ºC, 220 rpm for 2 hours. Transformation mix of 
100 µl was spread on LB agar plate containing 100 µg/ml ampicillin (Sigma, MO, 
USA), and incubated overnight at 37ºC for colony formation. Single colony selected 
from the LB agar plate was inoculated into 6 ml LB broth containing 100 µg/ml 
ampicillin and grown overnight as starter culture, which was then used to inoculate 150 
ml of LB broth with 100 µg/ml ampicillin. Plasmids were extracted using HiSpeed 
plasmid MIDI kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. 
Meanwhile, the transformed XL1-Blue cells were cryopreserved in LB broth with 15% 
glycerol (BDH, Poole, UK) and stored in -80ºC. 
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Appendix IX  
 
SDS-PAGE and Western Blots 
(A) Protein extraction from cell lines 
Oral cells were cultured in DMEM/F-12 complete medium until 70% confluent. Cells 
were lysed using cold RIPA lysis buffer containing 1% Halt
TM
 100x Protease Inhibitor 
Cocktail (Pierce, IL, USA), and 0.5% 200 mM Na3VO4 (Sigma, MO, USA). In general, 
100 μl of RIPA buffer was used per 100x20 mm dish. Cells were incubated with RIPA 
buffer on ice with gentle rocking for 15 min. Cell lysates were homogenized and DNA 
was sheared by passing the lysate through a 21-gauge needle for a few times. After 
centrifugation at 13,000g for 15 min at 4ºC, supernatants were harvested and stored at -
80ºC for further analysis.  
 
(B) Protein quantification 
Protein concentration was determined using modified Bradford assay. Briefly, 300 µl 
Coomassie Plus reagent (Pierce, IL, USA) was incubated with 10 µl of protein samples 
in a 96-well plate format for 10 min and absorbance was measured at 595 nm 
wavelength in a microplate reader (Thermo Fisher scientific, MA, USA). All samples 
were measured in triplicates and blank control was used to subtract background noise. 
Protein standards prepared from bovine serum albumin (BSA) with concentrations 
ranging between 0 to 2000μg were used to produce the standard curve for the 
determination of protein concentration of the samples as below: 
 
 
 
 
 
 
 
 
 
 
 
 
 
BSA standard curve 
y = 2225.8x
3
 - 1637.4x
2
 + 1128.9x - 2.8457
R
2
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Appendix IX, continued 
 
(C) SDS polyacrylamide gel electrophoresis 
Crude protein was mixed with 6x Laemmli buffer and denatured at 100ºC for 10 min to 
ensure that the proteins are in their denatured conformations. Protein samples of 50 μg 
were electrophoresed together with BenchMark Prestained protein ladder (Invitrogen, 
CA, USA) on a 4% stacking gel and separated in 12% resolving gel. Electrophoresis 
was carried out for 90 min at 120 V in SDS/Tris-glycine running buffer. 
 
(D) Western blotting 
Proteins were transferred onto 0.45 micron nitrocellulose membrane (Pierce, IL, USA) 
using the Mini Trans-Blot Electrophorectic Transfer Cell (Bio-Rad, CA, USA) in wet 
condition at 400 mA for 60 min. Membranes were blocked with 5% skimmed 
milk/TBST to prevent non-specific binding of antibodies to the membrane. Then, the 
following primary antibodies were used to probe the membrane: GNA12 at 1:200 
dilution (sc-409, Santa Cruz, USA) and IFITM3 at 1:1000 dilution (H00010410-M01, 
Abnova, Taiwan). Membranes were washed thoroughly with TBST before further 
probing it with the respective secondary antibodies conjugated to IRDye at 1:10000 
dilution (LICOR, Nebraska, USA). Protein bands were detected by infra-red detection 
method using the Odyssey scanner (LICOR, Nebraska, USA), and the intensity of the 
protein bands were measured by densitometry using the Odyssey software (LICOR, 
Nebraska, USA).  
Blots were stripped using 0.2% NaOH for 10 min and probed with anti-actin 
monoclonal antibody at 1:1000 dilution (MAB1501, Chemicon, USA) to control for 
loading variation, and further processed as described above.  
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Appendix IX, continued 
 
 
Reagents for SDS-PAGE and Western blotting 
12% resolving gel                  5% stacking gel 
Component Volume (ml)  Component Volume (ml) 
Water 3.3  Water 3.4 
1.5M Tris HCl (pH 8.8) 2.5  1M Tris HCl (pH 6.8) 0.63 
10% SDS 0.1  10% SDS 0.05 
30% Acrylamide 4.0  30% Acrylamide 0.83 
10% Ammonium persulfate 0.1  10% Ammonium persulfate 0.05 
TEMED 0.004  TEMED 0.005 
 
6x SDS gel loading buffer 
300mM Tris-HCl, pH 6.8 
600mM Dithiothreitol  
12% (w/v) SDS  
0.6% bromophenol blue  
60% (v/v) glycerol 
10x TBS 
NaCl                     80g 
KCl                         2g 
Tris base               30g 
Adjust to pH 8.0 
Distilled water up to 1L 
RIPA lysis buffer 
50mM Tris-HCl pH7.4 
1% NP-40 
150mM NaCl  
0.25% Na-deoxycholate  
1mM EDTA 
 
Transfer buffer 
24mM Tris base 
192mM glycine 
20% methanol 
 
1x Tris-glycine running buffer 
25mM Tris-base  
250mM Glycine, pH8.3  
0.1% (w/v) SDS  
 
6x Lameali buffer 
SDS                           1.2g 
Bromophenol blue     1.5mg 
Glycerol                      4.7ml 
0.5M Tris pH6.8         1.2ml 
Sterile water                 2.1ml 
DTT                              0.93g 
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Appendix X  
Selection of oral cancer cell line for in-vitro functional studies 
(A) GNA12  
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Figure 1: GNA12 mRNA expression in oral cancer cell lines. The mRNA level of 
GNA12 was normalized against GAPDH housekeeping gene. GNA12 expression in 15 
oral cancer cell lines was calibrated against 2 non-malignant primary keratinocytes 
(ORL218 and ORL232N). A RQ value of ≥ 2 indicates over-expression. All cultured 
cell lines displayed basal expression of GNA12. Cell line ORL150 was among those 
with low level of GNA12, hence was selected for exogenous expression studies. 
 
 
 
Figure 2: GNA12 protein expression in oral cancer cell lines. Basal expression of 
GNA12 was found in all cell lines, including the non-malignant primary keratinocytes 
(ORL218N and ORL232N). Protein lysate harvested from 293T cells transfected with 
GNA12 was used as positive control. 
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Appendix X, continued 
 
(B) IFITM3 
Oral cancer cell lines
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Figure 3: IFITM3 mRNA expression in oral cancer cell lines. The mRNA level of 
IFITM3 was normalized against GAPDH housekeeping gene. IFITM3 expression in 15 
oral cancer cell lines was calibrated against 2 non-malignant primary keratinocytes 
(ORL218 and ORL232N). Over-expression was determined at RQ ≥ 2. ORL207 cell 
line has the highest expression of IFITM3, whilst ORL188 demonstrated low level of 
IFITM3 expression. 
 
 
 
Figure 4: IFITM3 protein expression in oral cancer cell lines. Expression of IFITM3 
is indicated by the presence of the lower band. Majority of the oral cancer cell lines 
showed high levels of IFITM3 compared to the ORL218N. Meanwhile, ORL232N 
showed high basal level of IFITM3. Low level of IFITM3 protein was also detected in 
ORL188. Protein lysates from Hela cell line was used as positive control.  
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Appendix XI 
 
pLXRN retroviral vector information (Clontech) 
 
 
Location of features: 
 5’ MoMuSV LTR: 1-589 
 Ψ+ (packaging signal): 659-989 
 Multiple cloning site (MCS): 1006-1035 
 Rous sarcoma virus (RSV) promoter (PRSV): 1039-1350 
 Neomycin resistance gene (Neor):  
start codon: 1704-1706; stop codon: 2496-2498 
 3’ MoMuSV LTR: 3290-3883 
 Col E1 origin of replication: 4419 
 Ampicillin resistance gene (β-lactamase): start codon: 5181-5179 
 
Propagation in E. coli 
 Suitable host strains: DH5α, HB101 and other general purpose strains 
 Selectable  marker: plasmid confers resistance to ampicillin (100µg/ml) to E. 
coli host 
 E.coli replication origin: Col E1 
 Copy number: low 
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Appendix XII 
 
pLenti6.3 lentiviral vector information (Invitrogen) 
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Appendix XIII 
 
Normality test on sample distribution 
 
 
Test of normality for GNA12 QPCR analysis 
 
 
 
 
Test of normality for IFITM3 QPCR analysis 
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Appendix XIII, continued 
 
 
 
Test of normality for monolayer scratch assay 
 
 
 
 
 
 
 
Test of normality for Transwell invasion assay 
 
 
 
 
 
 
 
 
 
